Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

類似資料

• Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors
  著者:: Wang, Wei, 等
  出版事項: (2015)
• Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
  著者:: Chen, Z, 等
  出版事項: (2016)
• Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy
  著者:: Gong, Zimu, 等
  出版事項: (2017)
• Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia
  著者:: Prescott, Hillary, 等
  出版事項: (2011)
• Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options
  著者:: Jabbour, Elias J., 等
  出版事項: (2013)